Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Monteith

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Pharmaceutical Sciences|December 4, 2003
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeysRosie Z Yu, Richard S Geary, David K Monteith, et al.
Anti-Cancer Drug Design|July 1, 1997
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodentsD K Monteith, S P Henry, R B Howard, et al.
Toxicologic Pathology|June 5, 1999
Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeysD K Monteith, M J Horner, N A Gillett, et al.
Journal of Applied Toxicology : JAT|November 10, 2005
A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile redBartley W Halstead, Craig M Zwickl, Ryan E Morgan, et al.
Journal of Pharmaceutical Sciences|October 1, 1993
Degradation and inactivation of antitumor drugsJ A Benvenuto, T H Connor, D K Monteith, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administrationM J Graham, S T Crooke, D K Monteith, et al.
Mutation Research|August 20, 2005
Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicalsMohammed Islaih, Bartley W Halstead, Ibrahim A Kadura, et al.
Mutagenesis|April 25, 2002
Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotideScott P Henry, D K Monteith, J E Matson, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Pharmaceutical Sciences|December 4, 2003
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeysRosie Z Yu, Richard S Geary, David K Monteith, et al.
Anti-Cancer Drug Design|July 1, 1997
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodentsD K Monteith, S P Henry, R B Howard, et al.
Toxicologic Pathology|June 5, 1999
Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeysD K Monteith, M J Horner, N A Gillett, et al.
Journal of Applied Toxicology : JAT|November 10, 2005
A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile redBartley W Halstead, Craig M Zwickl, Ryan E Morgan, et al.
Journal of Pharmaceutical Sciences|October 1, 1993
Degradation and inactivation of antitumor drugsJ A Benvenuto, T H Connor, D K Monteith, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administrationM J Graham, S T Crooke, D K Monteith, et al.
Mutation Research|August 20, 2005
Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicalsMohammed Islaih, Bartley W Halstead, Ibrahim A Kadura, et al.
Mutagenesis|April 25, 2002
Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotideScott P Henry, D K Monteith, J E Matson, et al.
Pageof 4